Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03952884 · ClinicalTrials.gov registry record · NA

Skeletal Muscle Protein Synthetic Response to Amino Acid and Peptides

A NA study of Protein Metabolism, sponsored by University of Illinois at Urbana-Champaign.

Completed
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT03952884: Completed NA study of Protein Metabolism, sponsored by University of Illinois at Urbana-Champaign.

NCT03952884 is a NA study of Protein Metabolism that has completed, run by University of Illinois at Urbana-Champaign. The registered enrollment target is 10 participants, below the 50-participant average among 5 other Protein Metabolism trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03952884, a NA study of Protein Metabolism, has completed, sponsored by University of Illinois at Urbana-Champaign.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

Skeletal muscle quality is an important determinant of exercise performance and overall health. It is vital for not just movement, but also metabolizing nutrients. Protein from the diet can promote muscle protein synthesis for muscle recovery and growth. More importantly, doing so shifts net protein balance positively (e.g. protein synthesis is greater than protein breakdown) and promotes greater rates of muscle protein turnover. Leucine is an amino acid required to build muscle, but it also acts as a signaling molecule informing the muscle to start protein synthesis. Before reaching skeletal muscle, dietary protein is digested into small peptides and free amino acids. Rate of absorption from the intestine to the blood stream is significantly faster for peptides compared to amino acids. As amino acid availability in the blood is a precursor for muscle protein synthesis, our objective is to determine if the different absorption rates between free amino acid and peptides influence muscle protein synthetic and breakdown rates.

Primary Outcome

Mixed muscle protein synthesis rates will be assessed during the 3.5hr Postabsorptive period (e.g. non-fed state) and the 3hr postprandial period (e.g. fed state) for both experimental interventions (e.g. leucine and leucine peptide). This will allow us to assess the change in fractional synthetic rate from the Postabsorptive period to the postprandial period.

Conditions Studied

Interventions

  • BEHAVIORAL Resistance Exercise
  • DIETARY_SUPPLEMENT Leucine
  • BEHAVIORAL No Resistance Exercise
  • DIETARY_SUPPLEMENT Dileucine

Study Locations (1)

Illinois

  • Freer Hall - Urbana

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2019-05-03
Est. Completion 2019-11-20
Phase NA

What the finished NCT03952884 record still lists

NCT03952884 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 50-participant average among 5 other Protein Metabolism trials with a reported enrollment target (80% lower).

The record links to 1 condition, with Protein Metabolism appearing as the primary indexed condition, and to 4 interventions - of which Resistance Exercise is the first listed.

NCT03952884 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT03952884 about?

NCT03952884 is a clinical study titled "Skeletal Muscle Protein Synthetic Response to Amino Acid and Peptides". Skeletal muscle quality is an important determinant of exercise performance and overall health. It is vital for not just movement, but also metabolizing nutrients. Protein from the diet can promote muscle protein synthesis for muscle recovery and growth. More importantly, doing so shifts net protein...

What is the current status of trial NCT03952884?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2019-05-03. Estimated completion is 2019-11-20.

What conditions does trial NCT03952884 study?

This clinical trial studies the following conditions: Protein Metabolism.

What interventions are being tested in trial NCT03952884?

The interventions under investigation include: Resistance Exercise (BEHAVIORAL), Leucine (DIETARY_SUPPLEMENT), No Resistance Exercise (BEHAVIORAL), Dileucine (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03952884?

This trial is sponsored by University of Illinois at Urbana-Champaign, which has 129 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03952884 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Protein Metabolism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03952884, the US trial registry maintained by the National Library of Medicine. NCT03952884 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.